Travis Murdoch, MD

Travis Murdoch is CEO and President of Braveheart Bio and founder and former CEO of Human Immunology Biosciences (HI-Bio), a precision immunology company which was acquired by Biogen in 2024. Following the acquisition of HI-Bio, Travis joined Biogen’s leadership team, leading the West Coast Hub through multiple Phase 3 starts for HI-Bio’s lead program, felzartamab.  

Travis was previously a partner at Monograph Capital and an investor with Softbank Vision Fund. Earlier, Travis was a principal at Third Rock Ventures, and a consultant at McKinsey & Company.  Travis is a gastroenterologist and internist who worked with Northern communities in Canada. He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Travis studied immunology at Oxford University as a Rhodes Scholar and medicine at the University of Alberta.